Research programme: neurodegenerative disorder therapeutics - Kadimastem/Merck Serono

Drug Profile

Research programme: neurodegenerative disorder therapeutics - Kadimastem/Merck Serono

Latest Information Update: 05 Oct 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kadimastem; Merck Serono
  • Class
  • Mechanism of Action Glial cell modulators; Neurogenesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Multiple sclerosis; Neurodegenerative disorders

Most Recent Events

  • 29 Sep 2015 Kadimastem receives grant from the National Multiple Sclerosis Society for the development in nerve-insulating myelin in Multiple sclerosis
  • 07 Aug 2014 Early research in Neurodegenerative disorders in Israel (PO)
  • 01 May 2014 Early research is ongoing in Israel
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top